EBOS Group Limited (ASX: EBO) – EBOS’ stock remains slow on 12.2% rise in profit

Fisher & Paykel Healthcare and EBOS Group

EBOS Group today announced record financial performance for the period ended 30 June 2018, posting 12.2% rise in net profit after tax of $149.6 million. EBITDA grew 16.2% to $272.4 million in FY18.

Underlying NPAT was up 7.9% to $149.6 million and underlying EPS grew 7.8% to 98.5 cents in fiscal 2018. Group’s total revenue declined 0.2% to $7.6 million, driven by lower hepatitis C medicines sales and discontinuing sale of some animal care products.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

With the expansion in Institutional healthcare market, EBOS group acquired 14.4% interest in Medavisor, an Australian digital medication management company followed by the acquisition of New Zealand footcare consumer brand Gran’s Remedy.

The board declared final dividend of 35.5 cents per share, fully franked, bringing FY18 dividend to 68.5 cents per share, an increase of 8.7% on the prior year. The final dividend is payable on 12 October 2018.

Earnings per share was 98.5 cents per share, up 12.1% on FY17.

Despite announcing record financial results for FY18, EBO has seen needle price change of +0.21% to $19.10 on Thursday, 23 August 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report